Alzheimer's

News

London cab drivers’ brains to be studied for Alzheimer’s research

Asher Notheis -

November 1, 2021 3:56 pm

Healthcare

FDA panel criticizes agency approval of controversial $56,000 Alzheimer’s drug

David Hogberg -

July 28, 2021 9:33 pm

Healthcare

Prescription drug ‘sticker prices’ may rise in 2021 after years of decline

David Hogberg -

July 21, 2021 11:00 am

Healthcare

The group Public Citizen wants FDA chief Janet Woodcock removed from her post

Cassidy Morrison -

July 16, 2021 3:00 am

Thankfully, the scientific community isn't taking the FDA's non-scientific approach to kratom lying down. (AP Photo/Andrew Harnik)

Healthcare

FDA head invites investigation into agency contact with manufacturer of controversial Alzheimer’s treatment

Cassidy Morrison -

July 9, 2021 8:09 pm

Healthcare

FDA narrows eligibility for controversial $56,000 Alzheimer’s treatment

Cassidy Morrison -

July 8, 2021 7:14 pm

Healthcare

In cost-saving move, Medicare could limit patient access to Alzheimer’s treatment

Cassidy Morrison -

June 29, 2021 10:30 am

U.S. deterrence policy has generated plenty of criticism from Capitol Hill. But that has been aimed at the administration's supposedly narrow view of what constitutes an attack and unwillingness to spell out likely responses.

Healthcare

Controversial Alzheimer’s drug a godsend for a trial participant, but price tag could put it out of reach

Cassidy Morrison -

June 25, 2021 3:00 am

Healthcare

Liberal watchdog group pushes FDA leadership to resign over controversial Alzheimer’s treatment approval

Cassidy Morrison -

June 17, 2021 3:36 pm

Healthcare

Approval of controversial $56,000 Alzheimer’s treatment could add $57 billion to federal spending

Cassidy Morrison -

June 16, 2021 10:29 am

1...345 6 Page 4 of 6

Tag: Alzheimer's

London cab drivers’ brains to be studied for Alzheimer’s research

FDA panel criticizes agency approval of controversial $56,000 Alzheimer’s drug

Prescription drug ‘sticker prices’ may rise in 2021 after years of decline

The group Public Citizen wants FDA chief Janet Woodcock removed from her post

FDA head invites investigation into agency contact with manufacturer of controversial Alzheimer’s treatment

FDA narrows eligibility for controversial $56,000 Alzheimer’s treatment

In cost-saving move, Medicare could limit patient access to Alzheimer’s treatment

Controversial Alzheimer’s drug a godsend for a trial participant, but price tag could put it out of reach

Liberal watchdog group pushes FDA leadership to resign over controversial Alzheimer’s treatment approval

Approval of controversial $56,000 Alzheimer’s treatment could add $57 billion to federal spending

NEWS

POLICY

COMMENTARY

RESTORING AMERICA